Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malignancies. There are many challenges in translating this therapy for T cell disease, includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischer, Lauren C., Spencer, H. Trent, Raikar, Sunil S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936092/
https://www.ncbi.nlm.nih.gov/pubmed/31884955
http://dx.doi.org/10.1186/s13045-019-0801-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936092/
https://www.ncbi.nlm.nih.gov/pubmed/31884955
http://dx.doi.org/10.1186/s13045-019-0801-y

Ejemplares similares